DNA Script

DNA Script (South San Francisco, California) has launched its next-generation SYNTAX system, which it describes as “the world’s first DNA printer powered by enzymatic DNA Synthesis (EDS).”

The company recently announced that the SYNTAX system now offers support for q/dPCR assays, supporting same-day results.

DNA Script describes the offering as the first to offer a same-day turnaround for custom q/dPCR assays with a new generation of kits for the SYNTAX system. The system can design and print q/dPCR assays in as little as 8 hours.

“Since we released the world’s first commercial access to Enzymatic DNA Synthesis via the SYNTAX platform in the summer of 2021, we have made a number of improvements to advance benchtop DNA printing,” said Thomas Ybert, DNA Script co-founder and CEO, in a statement. “Given the many applications, and the urgent need to perform them quickly, in-house DNA printing on demand is becoming one of the most important technologies of th…

[Image from DNA Script]

DNA Script announced today that it raised $165 million in a Series C financing round, bringing its total capital raised to $280 million.

South San Francisco-based DNA Script earmarked the funds raised to accelerate expansion and commercialization for the company’s Syntax benchtop nucleic acid printer and to broaden its portfolio of products powered by enzymatic DNA synthesis (EDS) technology, according to a news release.

In June, the company launched Syntax, a fully integrated, automated printer powered by EDS technology. The company designed the DNA printer to synthesize 96 DNA oligos in parallel, comprised of up to 60 nucleotides in length and delivers them ready for use in molecular biology and genomics workflows without the need for additional handling.

“DNA Script believes that the next industrial revolution will be driven by life science and biology, and we st…